Thus, despite various initial data on the efficacy of IDO1 inhibitors in cancer immunotherapy, during recent clinical trials, adding epacadostat (an IDO1 inhibitor) to pembrolizumab (an ICB) had not made significant contributions to controlling metastatic melanomas. Here, IDO1 is linked to melanoma.